Latest News and Press Releases

New data on Helsinn’s oncology pipeline presented at American Society of Clinical Oncology (ASCO) Annual Meeting 2022 Lugano, Switzerland, June 02, 2022 - Helsinn Group (“Helsinn”), a fully...

Helsinn Establishes New R&D Hub in the U.S. to Support its Global Fully Integrated Targeted Therapy (FITT) Strategy New R&D hub will be based at U.S. subsidiary, Helsinn Therapeutics (U.S.),...

Helsinn appoints Dr Melanie Rolli as Group Chief Operating Officer Lugano, Switzerland, May 19, 2022 – Helsinn Group, a fully integrated, global biopharma company with a diversified pipeline of...

Helsinn to present data at upcoming AMMF’s 2022 European Cholangiocarcinoma Conference Lugano, Switzerland, May 11, 2022 - Helsinn Group (“Helsinn”), a fully integrated, global biopharma company with...

Juniper Biologics signs exclusive license agreement with Helsinn for infigratinib (INN) for the emerging markets* Lugano, Switzerland, and Singapore, 04 May 2022 – Juniper Biologics Pte Ltd , a...

Taiho Pharmaceutical Obtains Approval to Manufacture and Market NK1 Receptor Antagonist Arokaris® I.V. Infusion 235mg in Japan Tokyo, Japan, and Lugano, Switzerland March 28, 2022 - Taiho...

Helsinn Group and BridgeBio Pharma Announce Update to Strategic Collaboration to Develop, Manufacture and Commercialize Infigratinib in Oncology Indications in the U.S. Helsinn gains an exclusive...

Verity Pharmaceuticals™ and Helsinn Therapeutics sign exclusive agreement for the promotion of Akynzeo® and Valchlor® in Puerto Rico Toronto, Ontario and Lugano, Switzerland, February 16, 2022 ...

AnaCardio exercises option to license a program in heart failure from Helsinn Lugano, Switzerland and Stockholm, Sweden, February 3, 2022 - Helsinn Group (“Helsinn”), a fully integrated, global...

Helsinn Launches Fully Integrated Targeted Therapy (FITT) Strategy and Announces Leadership and Structural Changes Strategy focuses on developing and commercializing a differentiated pipeline of...